The FDA accepted the new drug application for iberdomide based on minimal residual disease negativity benefit shown in the ...
Five-Year Capital Spending Plan -- Remains at $1.9 billion, reaffirming a targeted 10% compounded annual rate base growth ...
Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for subcutaneous amivantamab and hyaluronidase-lpuj as a ...
Pharmaceutical Technology on MSN
Relay Therapeutics’ zovegalisib secures FDA BTD for advanced breast cancer
The BTD for zovegalisib is supported by data from the Phase I/II ReDiscover trial.
Otter Tail Corporation ( OTTR) Q4 2025 Earnings Call February 17, 2026 11:00 AM EST [Operator Instructions] There are currently no questions in the queue, but we will wait a brief moment in case ...
Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for subcutaneous amivantamab and hyaluronidase-lpuj as ...
Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2025. Below is a summary of business progress in 2025, financial performance for the year and the financial outlook ...
Designation supported by robust clinical data from ReDiscover trial with 600mg BID fasted and 400mg BID fed doses of zovegalisib in combination ...
SUMMIT NDA for bezuclastinib in patients with NonAdvSM submitted in December 2025; APEX NDA submission for bezuclastinib in patients with AdvSM ...
Akeso, Inc. (9926.HK) is pleased to announce that ivonescimab, its global first-in-class bispecific antibody targeting PD-1 and VEGF, has been granted its fifth Breakthrough Therapy Designation from t ...
Gisborne Girls’ High School welcomed its new principal Bindy Hannah today with a moving pōwhiri. Hannah said she never ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results